Efficacy of compound xueshuantong capsule in reducing cardiovascular diseases and associated ophthalmic complications: a multi-centre retrospective study

IF 2.2 4区医学 Q2 INTEGRATIVE & COMPLEMENTARY MEDICINE Journal of Herbal Medicine Pub Date : 2024-09-20 DOI:10.1016/j.hermed.2024.100943

{"title":"Efficacy of compound xueshuantong capsule in reducing cardiovascular diseases and associated ophthalmic complications: a multi-centre retrospective study","authors":"","doi":"10.1016/j.hermed.2024.100943","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>This study aims to explore the effectiveness and value of compound xueshuantong capsule (CXC) in the treatment of diseases by evaluating its potential to reduce cardiovascular diseases (CVDs) and ophthalmic complications.</div></div><div><h3>Methods</h3><div>A total of 5104 patients with fundus vascular diseases including retinal artery occlusion (RAO), retinal vein occlusion (RVO), diabetic retinopathy (DR), hypertensive retinopathy, periphlebitis of retina, age-related macular degeneration (AMD), central serous chorioretinopathy (CSC), and anterior ischaemic optic neuropathy (AION) were enroled across seven hospitals from 2002 to 2022. All participants were randomised categorised into two groups: CXC combination group (CXC alone or combined with hypoglycemic, lipid-lowering, or anti-hypertensive drugs, and other microcirculation and fundus angiopathy medications), and non-CXC group (only taking the above-mentioned medicines).</div></div><div><h3>Results</h3><div>Kaplan-Meier curves illustrated a lower incidence of cardio-cerebrovascular events and ophthalmic complications in CXC group compared with other group at a significant difference observed. Further stratification revealed a decreased risk of ophthalmic complications in CXC group, and supported by multivariate analysis through adjusting for baseline confounding factors.</div></div><div><h3>Discussion/Conclusions</h3><div>Our findings further confirmed the potential value of CXC in treating cardio-cerebrovascular diseases and associated ophthalmic complications, and accompanying with less side effects at the same time.</div></div>","PeriodicalId":56077,"journal":{"name":"Journal of Herbal Medicine","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Herbal Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2210803324001003","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

This study aims to explore the effectiveness and value of compound xueshuantong capsule (CXC) in the treatment of diseases by evaluating its potential to reduce cardiovascular diseases (CVDs) and ophthalmic complications.

Methods

A total of 5 104 patients with fundus vascular diseases including retinal artery occlusion (RAO), retinal vein occlusion (RVO), diabetic retinopathy (DR), hypertensive retinopathy, periphlebitis of retina, age-related macular degeneration (AMD), central serous chorioretinopathy (CSC), and anterior ischaemic optic neuropathy (AION) were enroled across seven hospitals from 2002 to 2022. All participants were randomised categorised into two groups: CXC combination group (CXC alone or combined with hypoglycemic, lipid-lowering, or anti-hypertensive drugs, and other microcirculation and fundus angiopathy medications), and non-CXC group (only taking the above-mentioned medicines).

Results

Kaplan-Meier curves illustrated a lower incidence of cardio-cerebrovascular events and ophthalmic complications in CXC group compared with other group at a significant difference observed. Further stratification revealed a decreased risk of ophthalmic complications in CXC group, and supported by multivariate analysis through adjusting for baseline confounding factors.

Discussion/Conclusions

Our findings further confirmed the potential value of CXC in treating cardio-cerebrovascular diseases and associated ophthalmic complications, and accompanying with less side effects at the same time.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

复方雪莲通胶囊对减少心血管疾病及相关眼科并发症的疗效：一项多中心回顾性研究

引言本研究旨在通过评估复方雪莲通胶囊（CXC）在减少心血管疾病（CVDs）和眼科并发症方面的潜力，探讨其在疾病治疗中的有效性和价值。方法从 2002 年到 2022 年，七家医院共招募了 5 104 名眼底血管疾病患者，包括视网膜动脉闭塞 (RAO)、视网膜静脉闭塞 (RVO)、糖尿病视网膜病变 (DR)、高血压视网膜病变、视网膜周围静脉炎、老年性黄斑变性 (AMD)、中心性浆液性脉络膜视网膜病变 (CSC) 和前部缺血性视神经病变 (AION)。所有参与者被随机分为两组：结果卡普兰-梅耶曲线显示，CXC 组与其他组相比，心脑血管事件和眼科并发症的发生率较低，差异显著。讨论/结论我们的研究结果进一步证实了 CXC 在治疗心脑血管疾病和相关眼科并发症方面的潜在价值，同时副作用较小。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Herbal Medicine INTEGRATIVE & COMPLEMENTARY MEDICINE-

CiteScore

3.90

自引率

0.00%

发文量

期刊介绍： The Journal of Herbal Medicine, the official journal of the National Institute of Medical Herbalists, is a peer reviewed journal which aims to serve its readers as an authoritative resource on the profession and practice of herbal medicine. The content areas of the journal reflect the interests of Medical Herbalists and other health professionals interested in the clinical and professional application of botanical medicines. The objective is to strengthen the research and educational base of herbal medicine with research papers in the form of case studies, original research articles and reviews, monographs, clinical trials and relevant in vitro studies. It also publishes policy statements, opinion pieces, book reviews, conference proceedings and profession related information such as pharmacovigilance reports providing an information source for not only the Herbal Practitioner but any Health professional with an interest in phytotherapy.